Alzheimer's drug slows mental decline
Alzheimer’s patients may be able to put hope in a new drug from Biogen Idec Inc., which has shown promise in a field of other expensive, but, unsuccessful drugs. Reports say that the drug, aducanumab, is the first experimental drug to show a statistically significant reduction in amyloid plaque, as well as a slowing of clinical impairment in patients with mild Alzheimer’s disease.
To conduct their initial trial with the drug, researchers tested 166 people divided into five groups. Four groups each received a different dose, and the fifth group received a placebo. According to interim data, Biogen’s treatment led to reductions in brain amyloid. Researchers were surprised to find that the plaque reduction was more pronounced as the dosage increased, and over time.
According to market analysts, the drug probably wouldn’t reach the public before 2020 due to years of more testing. Pending on the results of Biogen’s upcoming phase III trial coming up later this year, the company may start the process of seeking approval from the FDA.